Voyager Therapeutics Current Ratio 2014-2022 | VYGR
Voyager Therapeutics current ratio from 2014 to 2022. Current ratio can be defined as a liquidity ratio that measures a company's ability to pay short-term obligations.
| Voyager Therapeutics Current Ratio Historical Data |
| Date |
Current Assets |
Current Liabilities |
Current Ratio |
| 2022-03-31 |
$0.17B |
$0.10B |
1.68 |
| 2021-12-31 |
$0.14B |
$0.05B |
2.68 |
| 2021-09-30 |
$0.13B |
$0.03B |
4.73 |
| 2021-06-30 |
$0.15B |
$0.03B |
6.02 |
| 2021-03-31 |
$0.18B |
$0.03B |
7.10 |
| 2020-12-31 |
$0.20B |
$0.03B |
7.39 |
| 2020-09-30 |
$0.22B |
$0.04B |
5.14 |
| 2020-06-30 |
$0.25B |
$0.07B |
3.65 |
| 2020-03-31 |
$0.27B |
$0.07B |
3.76 |
| 2019-12-31 |
$0.31B |
$0.08B |
4.01 |
| 2019-09-30 |
$0.33B |
$0.08B |
4.09 |
| 2019-06-30 |
$0.34B |
$0.07B |
4.93 |
| 2019-03-31 |
$0.37B |
$0.06B |
6.21 |
| 2018-12-31 |
$0.16B |
$0.03B |
5.13 |
| 2018-09-30 |
$0.18B |
$0.03B |
6.08 |
| 2018-06-30 |
$0.20B |
$0.03B |
6.88 |
| 2018-03-31 |
$0.22B |
$0.03B |
7.13 |
| 2017-12-31 |
$0.17B |
$0.02B |
10.81 |
| 2017-09-30 |
$0.13B |
$0.02B |
6.12 |
| 2017-06-30 |
$0.15B |
$0.01B |
12.23 |
| 2017-03-31 |
$0.16B |
$0.01B |
14.56 |
| 2016-12-31 |
$0.18B |
$0.01B |
12.95 |
| 2016-09-30 |
$0.19B |
$0.02B |
9.96 |
| 2016-06-30 |
$0.21B |
$0.02B |
10.40 |
| 2016-03-31 |
$0.21B |
$0.02B |
8.91 |
| 2015-12-31 |
$0.20B |
$0.02B |
8.19 |
| 2015-09-30 |
$0.11B |
$0.02B |
4.65 |
| 2015-06-30 |
$0.00B |
|
0.00 |
| 2015-03-31 |
$0.00B |
|
0.00 |
| 2014-12-31 |
$0.01B |
$0.00B |
3.38 |
| 2014-09-30 |
$0.00B |
|
0.00 |
| 2014-06-30 |
$0.00B |
|
0.00 |
| 2014-03-31 |
$0.00B |
|
0.00 |
| 2013-12-31 |
$0.00B |
$0.00B |
0.03 |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Medical - Biomedical and Genetics |
$0.233B |
$0.037B |
|
Voyager Therapeutics, Inc. is a gene therapy company. It focuses on the development of treatments for patients suffering from severe diseases of the central nervous system. Its pipeline includes VY-AADC01, which is in Phase 1b clinical trials for treatment of Parkinson's disease and preclinical programs comprise VY-SOD101 for a monogenic form of amyotrophic lateral sclerosis, VY-FXN01 for Friedreich ataxia and VY-HTT01 for Huntington's disease as well as VY-SMN101 for neuromuscular disease. Voyager Therapeutics, Inc. is headquartered in Cambridge, Massachusetts.
|
